A Prescription Drug User Fee Act target date of August 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) ...

Among pediatric and adult patients with cystic fibrosis, the average number of chronic respiratory therapies used fell after ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for vanzacaftor/tezacaftor/deutivacaftor triple combination ...

Cystic fibrosis (CF) is a rare autosomal recessive disorder that affects numerous systems of the body. It is a complicated disease that differs from person to person. An autosomal recessive disorder ...

This year in review of 2025 milestones in idiopathic pulmonary fibrosis (IPF) features coverage of research on therapeutic efficacy presented at the American Thoracic Society 2025 International ...

A cystic fibrosis vest is a therapeutic tool. When worn, it provides compressions similar to manual chest percussions. Wearing the vest can help loosen sticky secretions so that a person can more ...

Babies may begin showing signs of cystic fibrosis shortly after they are born. Babies with cystic fibrosis may have prolonged jaundice, trouble passing meconium, and more frequent lung infections.

Bronchiectasis is a heterogeneous condition and may be encountered as a stand-alone pulmonary disease by primary care clinicians and specialists in pulmonary medicine. Bronchiectasis sometimes ...

Fundraising, training recognition, service expansion, and what's ahead for 2026 in the collision repair industry.